Glaxo Smith Kline has agreed to pay $3 billion to resolve multiple claims against it.  Among the allegations resolved by the settlement are its development and marketing of Avandia, a diabetes drug that has been linked to heart risks, improper marketing of Paxil and Wellbutrin between 1997 and 2004, and abusive Medicaid billing practices.

In 2010, GSK paid $2.4 billion to resolve several unrelated cases, $750 million of which resulted from a suit brought by Getnick & Getnick LLP regarding quality control deficiencies at GSK’s manufacturing plant in Cidra, Puerto Rico.

Read the entire article, “Glaxo to Pay U.S. $3 Billion to Settle”